DrugCite
Search

ICL

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Icl Adverse Events Reported to the FDA Over Time

How are Icl adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Icl, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Icl is flagged as the suspect drug causing the adverse event.

Most Common Icl Adverse Events Reported to the FDA

What are the most common Icl adverse events reported to the FDA?

Pyrexia
150 (2.63%)
Blood Creatinine Increased
147 (2.58%)
Pneumonia
111 (1.95%)
Renal Impairment
106 (1.86%)
Aspartate Aminotransferase Increase...
88 (1.54%)
Alanine Aminotransferase Increased
87 (1.53%)
Blood Urea Increased
87 (1.53%)
Platelet Count Decreased
80 (1.4%)
Blood Lactate Dehydrogenase Increas...
70 (1.23%)
Hepatic Function Abnormal
69 (1.21%)
Malignant Neoplasm Progression
69 (1.21%)
Show More Show More
Blood Alkaline Phosphatase Increase...
63 (1.1%)
Serum Ferritin Increased
63 (1.1%)
Decreased Appetite
60 (1.05%)
Nausea
60 (1.05%)
Gamma-glutamyltransferase Increased
59 (1.03%)
Anaemia
57 (1%)
Diarrhoea
55 (.96%)
Blood Bilirubin Increased
54 (.95%)
Malaise
52 (.91%)
Sepsis
51 (.89%)
Haemoglobin Decreased
50 (.88%)
C-reactive Protein Increased
49 (.86%)
Abdominal Pain
48 (.84%)
White Blood Cell Count Increased
48 (.84%)
Vomiting
47 (.82%)
Infection
46 (.81%)
Renal Disorder
44 (.77%)
Cough
43 (.75%)
Dehydration
43 (.75%)
White Blood Cell Count Decreased
43 (.75%)
Skin Ulcer
40 (.7%)
Renal Failure
37 (.65%)
Cardiac Failure
36 (.63%)
Condition Aggravated
36 (.63%)
Disease Progression
35 (.61%)
Pain
35 (.61%)
Dyspnoea
34 (.6%)
Ascites
33 (.58%)
Asthenia
32 (.56%)
Cellulitis
30 (.53%)
Liver Disorder
30 (.53%)
Depressed Level Of Consciousness
29 (.51%)
Hypoglycaemia
28 (.49%)
Rash
26 (.46%)
Urinary Tract Infection
26 (.46%)
Fall
25 (.44%)
Pleural Effusion
25 (.44%)
Nasopharyngitis
24 (.42%)
Neurosis
24 (.42%)
Anorexia
23 (.4%)
Erythema
23 (.4%)
Oedema Peripheral
23 (.4%)
Pain In Extremity
23 (.4%)
Blood Pressure Decreased
22 (.39%)
Abdominal Discomfort
21 (.37%)
Cerebral Infarction
20 (.35%)
Lung Disorder
20 (.35%)
Lymphocyte Count Decreased
20 (.35%)
Red Blood Cell Count Decreased
20 (.35%)
Retinal Haemorrhage
20 (.35%)
Myalgia
19 (.33%)
Agranulocytosis
18 (.32%)
Drug Ineffective
18 (.32%)
Fatigue
18 (.32%)
Fibrin D Dimer Increased
18 (.32%)
Fibrin Degradation Products Increas...
18 (.32%)
Gastrointestinal Haemorrhage
18 (.32%)
Loss Of Consciousness
18 (.32%)
Pancytopenia
18 (.32%)
Pertussis
18 (.32%)
Pulmonary Mass
18 (.32%)
Septic Shock
18 (.32%)
Visual Field Defect
18 (.32%)
Altered State Of Consciousness
17 (.3%)
Disseminated Intravascular Coagulat...
17 (.3%)
Neutrophil Count Decreased
17 (.3%)
Bronchopulmonary Aspergillosis
16 (.28%)
Cataract
16 (.28%)
Chest Pain
16 (.28%)
Upper Respiratory Tract Infection
16 (.28%)
Vitrectomy
16 (.28%)
Abdominal Pain Upper
15 (.26%)
Death
15 (.26%)
Dizziness
15 (.26%)
Gait Disturbance
15 (.26%)
Gastroenteritis
15 (.26%)
Headache
15 (.26%)
Muscular Weakness
15 (.26%)
Myelodysplastic Syndrome
15 (.26%)
Staphylococcal Infection
15 (.26%)
Arrhythmia
14 (.25%)
Constipation
14 (.25%)
Gastrointestinal Disorder
14 (.25%)
General Physical Health Deteriorati...
14 (.25%)
Haemoptysis
14 (.25%)
Hypokalaemia
14 (.25%)
Metabolic Acidosis
14 (.25%)
Multi-organ Failure
14 (.25%)
Pneumonia Aspiration
14 (.25%)
Pulmonary Alveolar Haemorrhage
14 (.25%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Icl, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Icl is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Icl

What are the most common Icl adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Icl, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Icl is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Icl According to Those Reporting Adverse Events

Why are people taking Icl, according to those reporting adverse events to the FDA?

Iron Overload
348
Myelodysplastic Syndrome
104
Aplastic Anaemia
50
Haemosiderosis
46
Thalassaemia Beta
16
Myelofibrosis
15
Show More Show More
Blood Iron Increased
11
Multiple Myeloma
6
Thalassaemia
5
Aplasia Pure Red Cell
4
Myeloproliferative Disorder
3
Anaemia
3
Serum Ferritin Increased
3
Acute Myeloid Leukaemia
3
Chronic Myeloid Leukaemia
2
Haemochromatosis
1
Thalassaemia Alpha
1
Leukaemia
1
Refractory Cytopenia With Multiline...
1
Lymphoma
1

Icl Case Reports

What Icl safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Icl. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Icl.